OptimizeRx acquires EvinceMed assets for $2M cash and up to 240,741 shares

OptimizeRx Corp

Asset purchase of EvinceMed Corp.; total consideration includes $2M cash and up to 240,741 common shares.
185,185 shares issued at closing; 55,556 held back for 12 months for indemnification adjustments.
Closing expected in Q2 2022; shares issued under Section 4(a)(2) exemption.
Acquisition strengthens OptimizeRx's product offering in patient engagement technology.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.